MaxCyte STX scalable transfection system launched in London



Of the approximately half-million children and adolescents in foster care in the U.S., experts estimate that 42 to 60 percent of them have emotional and behavioral problems. Despite the prevalence of mental health problems among foster children, little is known about how pre-existing mental health conditions affect their outcomes in foster care. A new study

Full Post: Study looks at how pre-existing mental health conditions affect outcomes in foster care

MaxCyte, Inc announced today the European launch of the MaxCyte STX Scalable Transfection System at SMi’s Cell-Based Assay Conference held in London, November 19 and 20, 2008.

MaxCyte is a sponsor at the conference.

“MaxCyte is pleased to have this opportunity to support SMi and the pharmaceutical industry in technical discussions on state of the art techniques and methods for the successful development of cell-based assays,” says Dr. Madhusudan Peshwa, Vice President of Research and Development at MaxCyte. “We believe that the MaxCyte(R) STX addresses many of the technical challenges facing researchers today, including reducing the time and expense needed to develop assays for high throughput screening. The MaxCyte(R) STX System enables the small and large scale transfection of primary cells, cell lines, and stem cells with single and multiple loading agents at the same time. About 10 billion cells can be transfected in less than 30 minutes. The MaxCyte STX can be a useful tool for biopharmaceutical companies to develop more relevant screening systems, which can increase the likelihood of finding successful drug candidates.”

According to MaxCyte CEO Doug Doerfler, “We are very pleased to announce the European launch of the MaxCyte(R) STX System. The MaxCyte STX is being viewed by the pharmaceutical industry as an enabling technology for cell modification for both research and larger scale cell-based applications in drug discovery. The ability of the system to operate effectively at any scale, with any molecule and with any cell, can significantly reduce bottlenecks and improve the productivity of drug discovery groups. The power of our technology — its speed, throughput, consistency, and efficiency in a closed, sterile, non-toxic environment — naturally translates into solving a major issue in the drug discovery sector: the rapid and cost effective development of cell-based assays to validate targets and conduct high throughput screens.”

Scientists from MaxCyte will be available at the SMi conference for discussions on the MaxCyte STX Scalable Transfection System technology and its applications.

http://www.maxcyte.com/

Link




Ricin, a lectin from the castor bean plant Ricinus communis is considered one of the most potent plant toxins. Ricin poisoning can cause severe tissue damage and inflammation and can result in death. Most accidental exposures occur by ingestion of the seeds of castor beans whereby the toxin is released after the seed coat is

Full Post: What are protective effects of anti-ricin A-chain aptamer?



VistaGen Therapeutics and the Wisconsin Alumni Research Foundation (WARF) have signed a license for human embryonic stem cell patents for the development and commercialization of stem cell-based research tools. VistaGen, a biotechnology company based in South San Francisco, is one of the world’s leading companies focused on using the power of stem cell technology to

Full Post: VistaGen, WARF sign license agreement for human embryonic stem cell technology



Sandia National Laboratories is seeking commercial partners to license or contribute to the continued development of a new lab-on-a-chip platform for high-throughput manipulation and interrogation of individual cells, one that enables quantitative analysis of cellular behaviors with unprecedented speed, resolution, sensitivity, and multiplexing. The Microscale Immune and Cell Analysis (MICA) platform is an extremely versatile

Full Post: New cell analysis platform developed - commercial partners sought



Stem Cell Sciences plc has announced that pioneering research describing a technique for creating authentic embryonic stem (ES) cells from rats has been published in the prestigious peer-reviewed journal, Cell. This publication is believed to be the first in which germ-line transmission from rat ES cells has been definitively demonstrated. It uses technology licensed exclusively

Full Post: New technique for creating authentic embryonic stem cells from rats



Screening with an ultrasound machine has proved highly successful in preventing stroke among children with sickle cell disease, by identifying children who are then preventively treated with blood transfusions. Over an eight-year period at The Children’s Hospital of Philadelphia, researchers found that the technique, transcranial Doppler ultrasonography (TCD), along with regular transfusions for children found

Full Post: Ultrasound helps prevent stroke in children with sickle cell disease